title: The role of some chemokines from the CXC subfamily in a mouse model of diabetic neuropathy.
abstract: The mechanism involved in the development of diabetic neuropathy is complex. Currently, it is thought that chemokines play an important role in this process. The aim of this study was to determine how the level of some chemokines from the CXC subfamily varies in diabetic neuropathy and how the chemokines affect nociceptive transmission. A single intraperitoneal (i.p.) injection of streptozotocin (STZ; 200 mg/kg) resulted in an increased plasma glucose. The development of allodynia and hyperalgesia was measured at day 7 after STZ administration. Using Antibody Array techniques, the increases in CXCL1 (KC), CXCL5 (LIX), CXCL9 (MIG), and CXCL12 (SDF-1) protein levels were detected in STZ-injected mice. No changes in CXCL11 (I-TAC) or CXCL13 (BLC) protein levels were observed. The single intrathecal (i.t.) administration of CXCL1, CXCL5, CXCL9, and CXCL12 (each in doses of 10, 100, and 500 ng/5 μL) shows their pronociceptive properties as measured 1, 4, and 24 hours after injection using the tail-flick, von Frey, and cold plate tests. These findings indicate that the chemokines CXCL1, CXCL5, CXCL9, and CXCL12 are important in nociceptive transmission and may play a role in the development of diabetic neuropathy.
authors: Institute of Pharmacology, Polish Academy of Sciences, 12 Smetna Street, 31-343 Krakow, Poland.
authors: Magdalena
authors: M
authors: Zychowska
authors: Institute of Pharmacology, Polish Academy of Sciences, 12 Smetna Street, 31-343 Krakow, Poland.
authors: Ewelina
authors: E
authors: Rojewska
authors: Institute of Pharmacology, Polish Academy of Sciences, 12 Smetna Street, 31-343 Krakow, Poland.
authors: Dominika
authors: D
authors: Pilat
authors: Institute of Pharmacology, Polish Academy of Sciences, 12 Smetna Street, 31-343 Krakow, Poland.
authors: Joanna
authors: 0000-0003-1986-7205
authors: J
authors: Mika
mesh_terms: D000818:Animals; D001522:Behavior, Animal; D001786:Blood Glucose / Q000032:analysis / Q000378:metabolism; D001835:Body Weight; D054360:Chemokine CXCL1 / Q000378:metabolism; D054377:Chemokine CXCL12 / Q000378:metabolism; D054365:Chemokine CXCL5 / Q000378:metabolism; D054370:Chemokine CXCL9 / Q000378:metabolism; D018925:Chemokines / Q000378:metabolism*; D003921:Diabetes Mellitus, Experimental / Q000378:metabolism*; D003929:Diabetic Neuropathies / Q000378:metabolism* / Q000473:pathology; D004195:Disease Models, Animal; D020869:Gene Expression Profiling; D006930:Hyperalgesia; D007249:Inflammation; D007274:Injections, Intraperitoneal; D008297:Male; D051379:Mice; D059225:Nociception; D013311:Streptozocin
chemical_list: D001786:Blood Glucose; D054360:Chemokine CXCL1; D054377:Chemokine CXCL12; D054365:Chemokine CXCL5; D054370:Chemokine CXCL9; D018925:Chemokines; C475895:Cxcl1 protein, mouse; C515256:Cxcl12 protein, mouse; C094739:Cxcl5 protein, mouse; C485969:Cxcl9 protein, mouse; D013311:Streptozocin